Latest Lead News

Viridis Mining and Minerals has delivered a landmark Pre-Feasibility Study for its Colossus Rare Earth Project, confirming robust economics and securing key strategic funding and land expansions in Brazil.

Triangle Energy has initiated legal proceedings against Strike Energy's subsidiary over a $3.84 million dispute tied to the L7 permit in the Perth Basin, escalating tensions in a key oil and gas project.

Spacetalk Ltd reports robust 28% growth in active mobile subscribers and a 20% rise in annual recurring revenue, fueled by strategic international expansion and a forthcoming software-led platform upgrade.

Harvest Technology Group reported improved EBITDA and secured new customers across mining, defence, and border control sectors in Q1 FY2026, supported by $2.13 million raised through convertible notes and loans.

Nelson Resources confirms high-grade gold assay results at its Yarri Project and partners with MEGA Resources to fully fund and manage development operations.

Mount Hope Mining has raised $2.48 million through a placement and share purchase plan to accelerate drilling at its Mt Solitary gold prospect and the broader 7.5km gold corridor in the prolific Cobar Basin.

Omnia Metals Group has successfully issued 54 million shares, raising $1.08 million as part of a broader $1.58 million placement. The company now looks to shareholders for approval to complete the remaining share and option issues.

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

Nick Scali Limited reported a robust $62 million underlying profit for FY25, completed its UK acquisition equity raise, and announced key leadership changes as it eyes accelerated growth in FY26.

CVC Limited is contemplating a fresh offer of Capital Notes, potentially including a reinvestment option for existing holders, contingent on market and regulatory conditions.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Challenger Limited has welcomed APRA’s proposed capital standards for longevity products, highlighting their potential to reduce capital requirements and stimulate growth in Australia’s retirement income sector.